Editorial: Advances in chemotherapy-resistant hepatocellular carcinoma

Shui Liu; Qiao Li; Yongzhi Li; Jiyao Sheng

doi:10.3389/fmed.2023.1325304

Editorial: Advances in chemotherapy-resistant hepatocellular carcinoma

Front Med (Lausanne). 2023 Nov 13:10:1325304. doi: 10.3389/fmed.2023.1325304. eCollection 2023.

Authors

Shui Liu^{1

2}, Qiao Li^{1

2}, Yongzhi Li^{1

2}, Jiyao Sheng^{1

2}

Affiliations

¹ Department of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Jilin University, Jilin University, Changchun, China.
² Jilin Engineering Laboratory for Translational Medicine of Hepatobiliary and Pancreatic Diseases, Changchun, China.

No abstract available

Keywords: chemotherapy; cholangiocarcinoma; combined chemotherapy; drug resistance mechanisms; hepatocellular carcinoma; molecular-targeted therapy.

Publication types

Editorial

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was funded by the Natural Science Foundation of China (81902484), China Postdoctoral Science Foundation (2020M670864), Youth Support Project of Jilin Association for Science and Technology (202028), the Natural Science Foundation of Jilin Province (YDZJ202301ZYTS080), Jilin Provincial Health Special Project (2019SCZT003), and Jilin Health and Healthy Youth Science and Technology Training Plan (2020Q017).